See more : SMT Scharf AG (S4A.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Replimune Group, Inc. (REPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Replimune Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MICT, Inc. (MICT) Income Statement Analysis – Financial Results
- Glittek Granites Limited (GLITTEKG.BO) Income Statement Analysis – Financial Results
- Mitsubishi Materials Corporation (MIMTF) Income Statement Analysis – Financial Results
- Nordea Inv European Small Cap S (NDIESCSKL1.CO) Income Statement Analysis – Financial Results
- HC SemiTek Corporation (300323.SZ) Income Statement Analysis – Financial Results
Replimune Group, Inc. (REPL)
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| Gross Profit | -2.66M | -2.45M | -4.58M | -4.14M | -1.81M | -148.00K | -109.00K | -122.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 174.96M | 126.53M | 79.55M | 56.75M | 38.76M | 22.17M | 13.52M | 6.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.81M | 50.55M | 38.77M | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Other Expenses | 0.00 | -5.68M | -1.06M | -665.00K | -16.00K | 451.00K | -2.06M | 626.00K |
| Operating Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Cost & Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Interest Income | 16.70M | 10.01M | 390.00K | 916.00K | 2.42M | 2.59M | 288.00K | 25.00K |
| Interest Expense | 0.00 | 4.16M | 2.22M | 3.06M | 1.92M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| EBITDA | -230.20M | -170.30M | -114.41M | -76.48M | -52.60M | -28.27M | -16.85M | -8.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -234.77M | -177.08M | -118.31M | -79.96M | -56.20M | -30.95M | -19.23M | -9.65M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.39M | 3.08M | 278.00K | -915.00K | 3.57M | 112.00K | -473.00K | 1.94M |
| Income Before Tax | -215.39M | -174.00M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 408.00K | 288.00K | 1.16M | 2.40M | 1.90M | 451.00K | -2.06M | 125.00K |
| Net Income | -215.79M | -174.28M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.36 |
| EPS Diluted | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.25 |
| Weighted Avg Shares Out | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 21.51M |
| Weighted Avg Shares Out (Dil) | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 30.84M |
Replimune to Present at the Jefferies Global Healthcare Conference
WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present...
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical...
Is a Surprise Coming for Replimune (REPL) This Earnings Season?
Replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present...
Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable
Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Recent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's Why
Replimune Group, Inc. (REPL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will...
Revisiting Replimune
Today, we revisit an intriguing oncology developmental company called Replimune Group, Inc. for the first time in more than a year. This week the company added drug giant Roche as a developmental partner and addressed its funding needs.
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present...
Source: https://incomestatements.info
Category: Stock Reports